CLINICAL TRIALS PROFILE FOR FEMCON FE
✉ Email this page to a colleague
All Clinical Trials for FEMCON FE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01344369 ↗ | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FEMCON FE
Condition Name
Clinical Trial Locations for FEMCON FE
Trials by Country
Clinical Trial Progress for FEMCON FE
Clinical Trial Phase
Clinical Trial Sponsors for FEMCON FE
Sponsor Name